Λ DNΛ design company
accelerating the future of
De novo design of context dependent regulatory and coding sequences using artificial intelligence.
Syngens combines decades of molecular biology research with cutting edge machine learning algorithms. Our platform enables the de novo design of regulatory sequences—promoter and 5' UTR— together with underlying context—host and coding sequence—to provide predictable output. This improves the efficiency and productivity of existing products and enables the development of entirely new products due to its novel approach and capabilities.
De novo design of artificial regulatory sequences to achieve defined goals such as maximising gene expression levels.
Optimising coding sequences in tandem with regulatory sequences depending on the host of choice.
Host of choice
Users either can define the host, or the platform can suggest the most suitable host based on the input coding sequence.
Biotechnology will be the manufacturing technology of the future, and synthetic biology (SynBio) has the potential to accelerate this development. Our platform can be applied to a wide range of areas including agriculture and food, sustainability and the environment, and health and medicine. It enables SynBio-based production of a range of bio-products relying on microorganisms as cell factories.
Current SynBio efforts rely on the combinatorial approaches using pre-characterised DNA parts. Our platform enables the rational de novo design of context-dependent regulatory sequences with predictable output.
Metabolic pathways involving cascade reactions require optimal expression levels for each of the genes involved. Our platform enables the optimised and synchronous expression of the genes in the pathways.
Current SynBio efforts are limited to existing pre-characterised DNA parts. Our platform enables the rational de novo design of regulatory sequences enabling the use of novel chassis as well as the model hosts.
The rational design of DNA is a difficult endeavour that currently relies on time-consuming, repeated trial-and-error procedures. Based on high accuracy predictions, our technology enables teams and researchers to modify gene expression. It enables design techniques that are no longer constrained, resulting in reduced DBTL-cycles. As a consequence, product development is faster and less expensive, speeding up SynBio-based productions.
Enable new opportunities that were not feasible in to do targeted experiments, and the use of novel chassis.
Increase efficiency relying on predictable gene expression and protein production. Save time and cost with fewer DBTL-cycles.
Enable the move from oil-based to SynBio-based production, and accelerate the use of microorganisms as cell-factories.
Syngens is a Norwegian startup operating within the domains of AI and synthetic biology.
Thank you for being part of Syngens' community.
Please enter valid email address.
© 2021 Syngens AS | Org number 926 086 014